

Paul J. Maddon, et al.
Serial No.: 09/891,119
Filed : June 25, 2001
Page 5

5' gaccagaaggaggaggtgcaattgctagtgttcggattgactgccaac (SEQ ID
NO 6)
gtcttcctcctccacgttaacgatcacaagcctaactgacggttgagc 5' (SEQ ID
NO 7)

REMARKS

The Notice stated that although a copy of the Sequence Listing in computer readable form had been previously submitted for the present application, the content of the computer readable form failed to comply with the requirements of 37 C.F.R. §§1.823. The Notice also stated that applicants must provide a substitute computer readable form (CRF) copy of the "Sequence Listing", a substitute paper or compact disk copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Finally, the Notice stated that the applicants must submit a statement that the content of the sequence listing information in the computer readable form is identical to the written (on paper or compact disk) sequence listing and, where applicable, includes no new matter, as required by 37 C.F.R. §§1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.821(d).

In reviewing their records pursuant to preparing a response to the Notice, it was noted that the specification of the application had not been amended to recite the sequence identification numbers as required by 37 C.F.R. §§1.821(d).

In response, applicants have amended the specification and claims as set forth above to set forth the sequence identification numbers. Furthermore, with this Amendment, applicants submit a paper copy of the Sequence Listing which is attached hereto as Exhibit C in compliance with the requirements of 37 C.F.R. §1.824. In addition applicants submit herewith a computer

Paul J. Maddon, et al.
Serial No.: 09/891,119
Filed : June 25, 2001
Page 6

readable form (CRF) copy of the "Sequence Listing" as Exhibit D as required by 37 C.F.R. §1.825(d). Further, applicants submit herewith as Exhibit E a Statement in Accordance with 37 C.F.R. §1.821(f), certifying that the substitute computer readable form containing the nucleic acid and/or amino acid sequences as required by 37 C.F.R. §1.821(e) contains the same information which was submitted as the "Sequence Listing". The attached sequence listing does not contain any new matter. Applicants respectfully request the entry of Exhibits C-E into the file of the present application.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorneys invite the Examiner to telephone at the number provided below.

No fee is deemed necessary with the filing of this Response. However if any fees are required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

Mark A. Farley

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Mark A. Farley 5-12-03
John P. White Date
Reg. No. 28,678
Mark A. Farley
Reg. No. 33,170

John P. White
Registration No. 28,678
Mark A. Farley
Registration No. 33,170
Attorneys for Applicant(s)
Cooper & Dunham, LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400